Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’
Lantern Pharma’s AI-driven RADR(R) platform integrates over 200 billion oncology-specific data points and underpins every stage of its precision oncology pipeline. The company has three lead drug candidates in clinical development, targeting major oncology markets including NSCLC, TNBC, and NHL. Starlight Therapeutics extends Lantern’s footprint into brain and CNS cancers, including pediatric indications supported by orphan and rare disease designations. Lantern has received multiple FDA designations including Fast Track, Orphan Drug, and Rare Pediatric Disease status across its portfolio, enhancing regulatory pathways. With approximately $19.7 million in cash and equivalents, the company is funded through at least mid-2026 to support…
